Abstract
The majority of malignant mesothelioma possesses the wild-type p53 gene with a homologous deletion of the INK4A/ARF locus containing the p14ARF and the p16INK4A genes. We examined whether forced expression of p53 inhibited growth of mesothelioma cells and produced anti-tumor effects by a combination of cisplatin (CDDP) or pemetrexed (PEM), the first-line drugs for mesothelioma treatments. Transduction of mesothelioma cells with adenoviruses bearing the p53 gene (Ad-p53) induced phosphorylation of p53, upregulated Mdm2 and p21 expression levels and decreased phosphorylation of pRb. The transduction generated cleavage of caspase-8 and -3, but not caspase-9. Cell cycle analysis showed increased G0/G1- or G2/M-phase populations and subsequently sub-G1 fractions, depending on cell types and Ad-p53 doses. Transduction with Ad-p53 suppressed viability of mesothelioma cells and augmented the growth inhibition by CDDP or PEM mostly in a synergistic manner. Intrapleural injection of Ad-p53 and systemic administration of CDDP produced anti-tumor effects in an orthotopic animal model. These data collectively suggest that Ad-p53 is a possible agent for mesothelioma in combination with the first-line chemotherapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Carbone M, Kratzke RA, Testa JR . The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 2–17.
Robinson BW, Musk AW, Lake RA . Malignant mesothelioma. Lancet 2005; 366: 397–408.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–2644.
Lee AY, Raz DJ, He B, Jablons DM . Update on the molecular biology of malignant mesothelioma. Cancer 2007; 109: 1454–1461.
Frizelle SP, Grim J, Zhou J, Gupta P, Curiel DT, Geradts J et al. Re-expression of p16INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 1998; 16: 3087–3095.
Yang CT, You L, Yeh CC, Chang JW, Zhang F, McCormick F et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92: 636–641.
Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA . Gene therapy of established mesothelioma xenografts with recombinant p16INK4a adenovirus. Cancer Gene Ther 2000; 7: 1421–1425.
Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM . p14(ARF) modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res 2001; 61: 5959–5963.
Hopkins-Donaldson S, Belyanskaya LL, Simoes-Wust AP, Sigrist B, Kurtz S, Zangemeister-Wittke U et al. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006; 8: 551–559.
St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K . Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53. Cancer Gene Ther 2000; 7: 749–756.
Giuliano M, Catalano A, Strizzi L, Vianale G, Capogrossi M, Procopio A . Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int J Mol Med 2000; 5: 591–596.
Pochampally R, Fodera B, Chen L, Shao W, Levine EA, Chen J . A 60 kd MDM2 isoform is produced by caspase cleavage in non-apoptotic tumor cells. Oncogene 1998; 17: 2629–2636.
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T et al. p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser46-phosphorylated p53. Cell 2000; 102: 849–862.
Zhao H, Traganos F, Darzynkiewicz Z . Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation. Cell Cycle 2008; 7: 3048–3055.
Ungar S, Van de Meeren A, Tammilehto L, Linnainmaa K, Mattson K, Gerwin BI . High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer 1996; 74: 1534–1540.
Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008; 7: 2034–2048.
Shinoura N, Sakurai S, Shibasaki F, Asai A, Kirino T, Hamada H . Co-transduction of Apaf-1 and caspase-9 highly enhances p53-mediated apoptosis in gliomas. Br J Cancer 2002; 86: 587–595.
Yang C, You L, Lin Y, Lin C, McCormick F, Jablons DM . A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. Anticancer Res 2003; 23: 33–38.
Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA . Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 1996; 112: 1372–1376.
Quist SR, Wang-Gohrke S, Köhler T, Kreienberg R, Runnebaum IB . Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status. Cancer Gene Ther 2004; 11: 547–554.
Eisold S, Linnebacher M, Ryschich E, Antolovic D, Hinz U, Klar E et al. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J Gastroenterol 2004; 10: 3583–3589.
Lu X, Errington J, Curtin NJ, Lunec J, Newell DR . The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 2001; 7: 2114–2123.
Giovannetti E, Backus HH, Wouters D, Ferreira CG, van Houten VM, Brakenhoff RH et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96: 769–775.
Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res 2005; 11: 7444–7453.
Acknowledgements
This work was partly supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare of Japan and a Grant-in-aid from the Nichias Corporation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Cancer Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Li, Q., Kawamura, K., Yamanaka, M. et al. Upregulated p53 expression activates apoptotic pathways in wild-type p53-bearing mesothelioma and enhances cytotoxicity of cisplatin and pemetrexed. Cancer Gene Ther 19, 218–228 (2012). https://doi.org/10.1038/cgt.2011.86
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2011.86
Keywords
This article is cited by
-
p53 dry gene powder enhances anti-cancer effects of chemotherapy against malignant pleural mesothelioma
Gene Therapy (2024)
-
Targeting FAcilitates Chromatin Transcription complex inhibits pleural mesothelioma and enhances immunotherapy
Journal of Experimental & Clinical Cancer Research (2023)
-
An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
Cell Death & Disease (2021)
-
Human gut derived-organoids provide model to study gluten response and effects of microbiota-derived molecules in celiac disease
Scientific Reports (2019)
-
The role of apoptosis defects in malignant mesothelioma pathogenesis with an impact on prognosis and treatment
Cancer Chemotherapy and Pharmacology (2019)